NCT03310008View on ClinicalTrials.gov

Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases

PHASE1UnknownINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 7, 2017

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2021

Conditions
Colon Cancer Liver Metastasis
Interventions
BIOLOGICAL

NKR-2 cells

The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).

Trial Locations (4)

1000

Institut Jules Bordet, Brussels

1200

Cliniques universitaires Saint-Luc, Brussels

3000

UZ Leuven, Leuven

6000

Grand Hôpital de Charleroi, Charleroi

Sponsors

Lead Sponsor

Celyad Oncology SA
All Listed Sponsors
lead

Celyad Oncology SA

INDUSTRY

NCT03310008 - Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases | Biotech Hunter | Biotech Hunter